MicroRNA-21 ablation exacerbates aldosterone-mediated cardiac injury, remodeling, and dysfunction

American Journal of Physiology. Endocrinology and Metabolism
Maryam SyedDamian G Romero

Abstract

Primary aldosteronism is characterized by excess aldosterone secretion by the adrenal gland independent of the renin-angiotensin system and accounts for ~10% of hypertensive patients. Excess aldosterone causes cardiac hypertrophy, fibrosis, inflammation, and hypertension. The molecular mechanisms that trigger the onset and progression of aldosterone-mediated cardiac injury remain incompletely understood. MicroRNAs (miRNAs) are endogenous, small, noncoding RNAs that have been implicated in multiple cardiac pathologies; however, their regulation and role in aldosterone-mediated cardiac injury and dysfunction remains mostly unknown. We previously reported that microRNA-21 (miR-21) is the most upregulated miRNA by excess aldosterone in the left ventricle in a rat experimental model of primary aldosteronism. To elucidate the role of miR-21 in aldosterone-mediated cardiac injury and dysfunction, miR-21 knockout mice and their wild-type littermates were treated with aldosterone infusion and salt in the drinking water for 2 or 8 wk. miR-21 genetic ablation exacerbated aldosterone/salt-mediated cardiac hypertrophy and cardiomyocyte cross-sectional area. Furthermore, miR-21 genetic ablation increased the cardiac expression of fibrosis an...Continue Reading

References

Dec 1, 1990·Circulation Research·C G BrillaK T Weber
Oct 11, 1994·The American Journal of Physiology·P C DolberJ C Greenfield
Jun 1, 1994·The Journal of Clinical Investigation·M YoungJ Funder
Sep 15, 2001·American Journal of Physiology. Heart and Circulatory Physiology·S D ZimmermanR J McCormick
Jan 5, 2002·The New England Journal of Medicine·K T Weber
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Oct 18, 2002·American Journal of Physiology. Heart and Circulatory Physiology·Ricardo RochaJohn A Delyani
Jan 1, 1956·Annals of Internal Medicine·J W CONN, L H LOUIS
Mar 6, 2004·The Journal of Clinical Endocrinology and Metabolism·Paolo MulateroWilliam F Young
Oct 15, 2005·Development·Tingting Du, Phillip D Zamore
Aug 26, 2006·Nature Clinical Practice. Nephrology·Cecilia Mattsson, William F Young
Nov 17, 2006·Proceedings of the National Academy of Sciences of the United States of America·Eva van RooijEric N Olson
Jan 19, 2007·Nature Reviews. Genetics·Kevin Chen, Nikolaus Rajewsky
Jan 20, 2007·Circulation Research·Danish SayedMaha Abdellatif
Mar 30, 2007·Clinical Science·Morag J YoungAmanda J Rickard
Apr 14, 2007·The Journal of Clinical Investigation·Naohiro YamaguchiGerhard Meissner
May 15, 2007·Journal of Molecular and Cellular Cardiology·Mariko TatsuguchiDa-Zhi Wang
May 18, 2007·Annual Review of Cell and Developmental Biology·Natascha Bushati, Stephen M Cohen
May 26, 2007·The American Journal of Pathology·Yunhui ChengChunxiang Zhang
Jul 4, 2007·Circulation·Thomas ThumJohann Bauersachs
Aug 8, 2007·Hypertension·David A Calhoun
Aug 9, 2007·Clinical Science·Annis M Marney, Nancy J Brown
Mar 29, 2008·Science·Oliver Hobert
May 30, 2008·Molecular Biology of the Cell·Danish SayedMaha Abdellatif
Jun 12, 2008·Physiological Genomics·Michael V G LatronicoGianluigi Condorelli
Jun 13, 2008·Nature Protocols·Thomas D Schmittgen, Kenneth J Livak
Jun 17, 2008·The Journal of Clinical Endocrinology and Metabolism·John W FunderUNKNOWN Endocrine Society
Aug 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Eva van RooijEric N Olson
Oct 15, 2008·Nature Reviews. Genetics·Alex S Flynt, Eric C Lai
Mar 4, 2009·Nature Cell Biology·Julia WinterSven Diederichs
Apr 2, 2009·Journal of Molecular and Cellular Cardiology·Yunhui ChengChunxiang Zhang
Aug 27, 2009·The Journal of Biological Chemistry·Shimin DongChunxiang Zhang
Sep 10, 2009·The Journal of Clinical Endocrinology and Metabolism·Michael Stowasser
Mar 3, 2010·Circulation·Eric M SmallEric N Olson
Apr 21, 2010·The Journal of Biological Chemistry·Danish SayedMaha Abdellatif
Jul 14, 2010·Journal of Cardiovascular Pharmacology·Johann Bauersachs
Aug 10, 2010·American Journal of Physiology. Lung Cellular and Molecular Physiology·Joy SarkarJ Usha Raj
Oct 28, 2010·The Journal of Clinical Investigation·David M PatrickEric N Olson
Jan 21, 2011·Nature·Eric M Small, Eric N Olson
Apr 6, 2011·Current Opinion in Cardiology·Mingyue HanMaha Abdellatif

❮ Previous
Next ❯

Citations

Feb 11, 2020·PloS One·Ken WatanabeMasafumi Watanabe
May 18, 2020·Journal of Toxicology and Environmental Health. Part a·Hao ChenHaiyan Tong
Jun 17, 2020·Clinical Science·Shaojun LiShufeng Li
Aug 22, 2020·American Journal of Hypertension·Nathanne S FerreiraErnesto L Schiffrin
Feb 14, 2021·In Vitro Cellular & Developmental Biology. Animal·Haihua GengHongzhuan Sheng
Feb 13, 2021·Life Sciences·Xuping LiYuanyuan Cheng
May 19, 2020·Matrix Biology : Journal of the International Society for Matrix Biology·Mohammad AlQudahMichael P Czubryt
Apr 4, 2021·International Journal of Molecular Sciences·Jacob E PruettLicy L Yanes Cardozo
Jul 28, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Jun ZhangLijun Liu
Dec 18, 2021·Endocrinology·Cristian A CarvajalCarlos E Fardella

❮ Previous
Next ❯

Datasets Mentioned

BETA
GM121334

Methods Mentioned

BETA
antisense oligonucleotides
PCR
protein assay
X-ray
transgenic

Software Mentioned

GraphPad
Primer3
ImageJ
VisualSonics Advanced Cardiovascular
GraphPad Prism
VisualSonics

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiovascular Homeostasis

Cardiovascular regulation and homeostasis is important in maintaining health and dysfunction may lead to cardiovascular diseases. Nitric oxide and vascular endothelium are one of many molecules involved in the homeostatic mechanism. Here is the latest research on cardiovascular homeostasis.